Equities research analysts expect that Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) will announce earnings of ($0.62) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Aerie Pharmaceuticals’ earnings, with estimates ranging from ($0.63) to ($0.61). Aerie Pharmaceuticals reported earnings per share of ($0.67) in the same quarter last year, which would indicate a positive year over year growth rate of 7.5%. The company is expected to issue its next earnings report on Wednesday, November 1st.

According to Zacks, analysts expect that Aerie Pharmaceuticals will report full year earnings of ($2.53) per share for the current financial year, with EPS estimates ranging from ($2.60) to ($2.48). For the next financial year, analysts anticipate that the company will report earnings of ($2.03) per share, with EPS estimates ranging from ($2.39) to ($1.77). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Aerie Pharmaceuticals.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.02.

A number of research analysts have issued reports on the stock. Needham & Company LLC reissued a “buy” rating and set a $65.00 price objective on shares of Aerie Pharmaceuticals in a research report on Sunday. Zacks Investment Research raised shares of Aerie Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $66.00 target price on the stock in a research report on Monday, July 24th. BidaskClub raised shares of Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, July 24th. Mizuho began coverage on shares of Aerie Pharmaceuticals in a research report on Wednesday, September 6th. They issued a “buy” rating and a $70.00 target price on the stock. Finally, ValuEngine raised shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have given a buy rating to the company. Aerie Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $66.36.

Aerie Pharmaceuticals (NASDAQ AERI) traded down 2.62% on Monday, hitting $52.00. 370,670 shares of the company’s stock were exchanged. The stock’s market cap is $1.89 billion. The firm has a 50 day moving average price of $54.83 and a 200-day moving average price of $50.04. Aerie Pharmaceuticals has a 52-week low of $32.05 and a 52-week high of $61.30.

COPYRIGHT VIOLATION WARNING: “Analysts Anticipate Aerie Pharmaceuticals, Inc. (AERI) to Post -$0.62 EPS” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/09/21/analysts-anticipate-aerie-pharmaceuticals-inc-aeri-to-post-0-62-eps.html.

Hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. grew its position in Aerie Pharmaceuticals by 28.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 223,053 shares of the company’s stock valued at $10,115,000 after purchasing an additional 49,473 shares during the last quarter. AXA purchased a new stake in Aerie Pharmaceuticals during the 2nd quarter valued at about $10,961,000. BlackRock Inc. grew its position in Aerie Pharmaceuticals by 113,376.8% during the 1st quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock valued at $117,951,000 after purchasing an additional 2,598,596 shares during the last quarter. Boulegeris Investments Inc. grew its position in Aerie Pharmaceuticals by 5.2% during the 2nd quarter. Boulegeris Investments Inc. now owns 79,525 shares of the company’s stock valued at $4,179,000 after purchasing an additional 3,900 shares during the last quarter. Finally, Parametric Portfolio Associates LLC grew its position in Aerie Pharmaceuticals by 5.8% during the 1st quarter. Parametric Portfolio Associates LLC now owns 68,398 shares of the company’s stock valued at $3,102,000 after purchasing an additional 3,739 shares during the last quarter. 94.64% of the stock is currently owned by institutional investors.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Get a free copy of the Zacks research report on Aerie Pharmaceuticals (AERI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.